Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication

Drug–drug interactions are of significant concern in clinical practice in oncology, particularly in patients receiving Cyclin-dependent kinase (CDK) 4/6 inhibitors, which are typically exposed to long-term regimens. This article presents the highlights from the ‘First Workshop on Pharmacology and Ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Bellet, Meritxell, Ahmad, Faten, Villanueva, Rafael, Valdivia, Carolina, Palomino-Doza, Julián, Ruiz, Ada, Gonzàlez, Xavier, Adrover, Encarna, Azaro, Analía, Valls-Margarit, Maria, Parra, Josep Lluís, Aguilar, Juan, Vidal, Maria, Martín, Anastasi, Gavilá, Joaquín, Escrivá-de-Romaní, Santiago, Perelló, Antonia, Hernando, Cristina, Lahuerta, Ainhara, Zamora, Pilar, Reyes, Victoria, Alcalde, María, Masanas, Helena, Céliz, Pamela, Ruíz, Isabel, Gil, Miguel, Seguí, Miguel Àngel, de la Peña, Lorena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
CDK4/6 Inhibitors in Breast Cancer: A Lot of Data, A Lot of Questions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535716/
https://www.ncbi.nlm.nih.gov/pubmed/31205497
http://dx.doi.org/10.1177/1758835919833867

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535716/
https://www.ncbi.nlm.nih.gov/pubmed/31205497
http://dx.doi.org/10.1177/1758835919833867

Ejemplares similares